Zantac (ranitidine) litigation is a split battlefield. The federal MDL was effectively killed in December 2022 when Judge Rosenberg excluded all ten of plaintiffs’ general causation experts under Daubert in a 341-page ruling — collapsing 80,000+ federal cases. The 11th Circuit appeal was argued October 2025; ruling pending. In Delaware, the trial court allowed experts (May 2024) but the Delaware Supreme Court reversed that in July 2025, sending cases back for stricter review. Illinois state trials have produced 8 consecutive defense verdicts or mistrials. GSK settled ~80,000 cases for up to $2.2B; Sanofi and Pfizer also settled. Boehringer Ingelheim is the last major defendant still fighting. Campaign outlook is borderline — the science and jury record are unfavorable.
NDMA (N-nitrosodimethylamine), a probable human carcinogen, is produced when ranitidine degrades over time or at elevated temperatures. Bladder cancer has the strongest causation link; colorectal and prostate cancer claims have been weakest. The federal MDL Daubert ruling found all ten plaintiffs’ causation experts unreliable — the most damaging mass tort Daubert loss in recent history. State courts are not bound by this ruling but the Delaware Supreme Court has now aligned its standard with federal Daubert. Science remains contested.
The federal MDL was effectively ended in Dec. 2022 when Judge Rosenberg excluded all 10 plaintiff causation experts under Daubert — the largest mass tort Daubert loss on record. The 11th Circuit heard appeal Oct. 2025; ruling pending. Delaware Supreme Court has aligned with federal Daubert. Illinois state trials have produced 8 consecutive defense verdicts or mistrials.